Oct. 18, 2021– A new federal government report could add momentum to efforts on Capitol Hill to end limitations on 340B price discounts for orphan drugs purchased by certain safety-net hospitals. The report suggests that drug companies might be seeking orphan status for their products to maximize revenues and avoid paying 340B discounts on drugs widely used to treat common … [Read more...]
Congress Urged to Loosen Limits on 340B Discounts for Orphan Drugs
June 29, 2020— A pair of researchers is calling on Congress to relax the limitations on 340B price discounts for orphan drugs at safety-net hospitals during the national response to the COVID-19 pandemic. In an opinion piece posted June 25 in Health Affairs, they note that many of the drugs being tested to treat or prevent COVID are considered orphan drugs – meaning they were … [Read more...]